News

All Categories

12 December 2023

How a Sydney VC made 13 times its money on one start-up investment

News, The Australian Financial Review

29 November 2023

US FDA Grants the BiVACOR Total Artificial Heart IDE Approval for First-in-Human Early Feasibility Study

Bivacor team

19 October 2023

Employment Hero secures $263m in year’s biggest capital raising

News, The Australian Financial Review

09 October 2023

How this AI startup used venture debt to fuel customer acquisition

18 July 2023

A leading VC’s outlook on capital for founders right now

18 June 2023

Vaxxas opens world-class manufacturing facility to produce needle-free vaccine patch

News, Announcement

07 June 2023

Survival of the fittest as ‘zombie’ start-ups stagger through winter

News, The Australian Financial Review

12 April 2023

What boxes must a start-up tick to get VC funding today?

News, The Australian Financial Review

30 March 2023

OneVentures pumps up artificial heart group BiVACOR

News, The Australian Financial Review

20 February 2023

Venture fundraising in US hits 9-year low

12 January 2023

What venture capital funds expect in 2023

14 December 2022

Australian VCs went earlier and smaller with deals in 2022

News, The Australian Financial Review

11 December 2022

Froth and bubble to normalise for venture capital startup investment

06 December 2022

Needle-free vaccine innovator banks $34m

News, The Australian Financial Review

19 September 2022

Venture Credit in Australia — Our first report alongside the Tech Council of Australia

04 July 2022

Interview with Ben Sze, Edrolo Co-CEO & Co-Founder

16 May 2022

Venture debt — Now is the time

12 April 2022

Tech gold rush continues as $2bn VC funding push hits the street

News, The Australian Financial Review

22 February 2022

Investment Notes: Kepler Analytics

Blog Post, Investment Notes

01 February 2022

Vale Grant Chamberlain

The Australian Financial Review, Announcement

17 December 2021

Women making a difference in venture capital

News, The Australian

18 November 2021

E-bike subscription service Zoomo raises $60M Series B to disrupt last-mile delivery

10 November 2021

Vaxxas recognised in the Top 10 healthcare startups in Australia, 2021

19 October 2021

Blade Therapeutics Initiates Additional Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis

decor decor decor
decor decor decor decor decor